Arcturus Therapeutics Holdings Inc. (NASDAQ:ARCT), a commercial-stage biotechnology company with a market capitalization of $446.4 million specializing in mRNA therapeutics and vaccines, stands at a ...

Oil and gas companies Arcturus Corp. and Aschere Energy LLC, along with founder Leon Ali Parvizian, must pay more than $10 million to remedy an allegedly fraudulent securities offering, a Texas ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

In a report released today, Ed Arce from H.C. Wainwright maintained a Buy rating on Arcturus Therapeutics (ARCT – Research Report), with a ...

Arcturus Therapeutics Holdings Inc. (the "Company", "Arcturus", Nasdaq: ARCT), a commercial messenger RNA medicines company ...

Arcturus Therapeutics Holdings Inc. stock is down 46% since Sept. 2023 coverage; mRNA sector faces headwinds with public skepticism (35% comfortable with technology) and challenges translating ...

Collectively, these elements underscore Arcturus Therapeutics’ capacity for innovation and market penetration, justifying the Buy rating. ARCT’s price has also changed moderately for the past ...

The co-development and project finance agreement will accelerate deployment of Skyven's cutting-edge, "decarbonizing" heat-pump technology at industrial manufacturing facilities, reducing emissions ...

This capital helps fund our Energy-as-a-Service offering, allowing us to deploy Arcturus at industrial <a target=_blank href= ...

BTIG Research began coverage on shares of Arcturus Therapeutics (NASDAQ:ARCT – Get Free Report) in a research report issued on Tuesday, MarketBeat reports. The brokerage set a “buy” rating and a ...